<DOC>
	<DOC>NCT00852995</DOC>
	<brief_summary>This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care.</brief_summary>
	<brief_title>Dose Finding Study of HP802-247 in Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<criteria>Provide informed consent. Willing to comply with protocol instructions, including allowing all study assessments. Have a venous leg ulcer (venous etiology)between the knee and ankle, at or above the malleolus. Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence. Target ulcer duration greater than or equal to 6 weeks but less than or equal to 24 months. Women who are pregnant or lactating Therapy with another investigational agent within thirty (30) days of Screening, or during the study. A target ulcer of nonvenous etiologies. Refusal of or inability to tolerate compression therapy. Therapy of the target ulcer with tissueengineered cellbased skin equivalents within 30 days preceding the Screening Visit. Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Venous Leg Ulcer (VLU)</keyword>
	<keyword>Venous Stasis Ulcer (VSU)</keyword>
	<keyword>VLU</keyword>
	<keyword>VSU</keyword>
	<keyword>Leg Ulcer</keyword>
	<keyword>Leg Wound</keyword>
</DOC>